5 Best Immunotherapy Stocks To Buy Now

In this article, we discuss 5 best immunotherapy stocks to buy now. If you want to read about some more immunotherapy stocks, go directly to 10 Best Immunotherapy Stocks To Buy Now.

5. Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)

Number of Hedge Fund Holders: 15     

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) is a clinical-stage biopharmaceutical company that discovers and develops therapies for the treatment of Alzheimer’s disease. It is one of the best immunotherapy stocks to invest in. The shares have rallied in the past few weeks on the back of promising results from a late-stage data for an experimental Alzheimer’s therapy, Lecanemab, by rivals of the firm. In the trial involving nearly 1,800 patients, the amyloid-targeting monoclonal antibody cut the cognitive and functional decline in the early stage of Alzheimer’s by 27%, compared to placebo. 

On October 05, BTIG analyst Thomas Shrader kept a Buy rating on Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) stock and raised the price target to $22 from $15, underlining that recent positive Lecanemab data from Biogen supports the therapeutic rationale of Acumen’s ACU193, increasing the modeled probability of success from 30% to 40%.  

At the end of the second quarter of 2022, 15 hedge funds in the database of Insider Monkey held stakes worth $85.5 million in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), compared to 16 the preceding quarter worth $65.4 million.